CareDx Inc (CDNA) Expected to Post Quarterly Sales of $21.74 Million
Equities analysts forecast that CareDx Inc (NASDAQ:CDNA) will report sales of $21.74 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for CareDx’s earnings. The lowest sales estimate is $21.48 million and the highest is $21.92 million. CareDx reported sales of $12.50 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 73.9%. The firm is expected to report its next quarterly earnings results on Thursday, March 28th.
On average, analysts expect that CareDx will report full-year sales of $74.80 million for the current fiscal year, with estimates ranging from $74.54 million to $74.97 million. For the next financial year, analysts anticipate that the company will post sales of $101.27 million, with estimates ranging from $97.97 million to $104.54 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for CareDx.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.42). CareDx had a negative return on equity of 125.24% and a negative net margin of 113.89%. The company had revenue of $21.18 million for the quarter, compared to the consensus estimate of $18.47 million.
In other CareDx news, major shareholder Neil Gagnon sold 108,599 shares of the firm’s stock in a transaction dated Wednesday, October 31st. The shares were sold at an average price of $27.05, for a total value of $2,937,602.95. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Peter Maag sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $23.10, for a total transaction of $346,500.00. Following the completion of the transaction, the insider now directly owns 439,747 shares in the company, valued at approximately $10,158,155.70. The disclosure for this sale can be found here. Insiders sold 201,454 shares of company stock worth $5,300,859 in the last three months. 3.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. bought a new position in CareDx in the third quarter worth about $124,000. Prospect Capital Advisors LLC increased its stake in shares of CareDx by 12.6% in the third quarter. Prospect Capital Advisors LLC now owns 56,300 shares of the company’s stock valued at $1,624,000 after purchasing an additional 6,300 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in shares of CareDx by 7.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 87,748 shares of the company’s stock valued at $1,074,000 after purchasing an additional 6,418 shares during the period. Caxton Associates LP acquired a new stake in shares of CareDx in the third quarter valued at approximately $201,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of CareDx in the third quarter valued at approximately $201,000. 72.69% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CDNA stock traded up $1.23 during trading hours on Friday, hitting $26.29. 9,050 shares of the company were exchanged, compared to its average volume of 827,925. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.36 and a current ratio of 2.65. CareDx has a one year low of $4.92 and a one year high of $30.15. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -34.99 and a beta of 1.06.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Article: Why do companies issue stock splits?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.